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Background
Loss-of-function mutations in CECR1, encoding adeno-
sine deaminase-2 (ADA2), have been associated with a
spectrum of vascular and inflammatory phenotypes, ran-
ging from early-onset vasculopathy manifesting as recur-
rent stroke, to systemic vasculitis manifesting as
polyarteritis nodosa (PAN) and Sneddon’s Syndrome.
Objectives
Knowledge about the ADA2 genotype and phenotype
has only recently started to emerge. We aimed to
further characterize the genotype-phenotype spectrum
associated with CECR1 mutations.
Patients and methods
19 newly diagnosed DADA2 patients and 92 DNA sam-
ples of the North American cohort with PAN were
screened for mutations in CECR1 by Sanger sequencing
of all coding exons.
Results
14/19 patients were homozygous or compound heterozy-
gous for rare or novel missense mutations in the coding
region of CECR1. In 5 patients, we have detected only
one likely disease-associated mutation; further analysis is
necessary to identify a possible genomic deletion or a
second mutation in the non-coding region of CECR1. We
have found three rare missense mutations that were not
previously associated with DADA2: A357T, G358R, and
L249P. More importantly, we have identified four novel
mutations that cause DADA2: T129P, K55del, N370K
and N423K. The R169Q mutation is a founder mutation
in the Dutch population, while the G47R mutation is a
founder mutation in the Middle Eastern and Pakistani
populations.
In the PAN cohort, we identified 6/92 patients with
mutations in CECR1. Three patients carry biallelic homo-
zygous or compound heterozygous mutations, and three
patients are carriers for a single mutation in CECR1.
Four rare variants are reported in Ensemble or ExAC,
but they have not been previously associated with PAN:
P106S, F355L, V349I, and T65M. We have identified one
novel mutation in the cohort with PAN: E328K.
Conclusion
The CECR1 gene is highly polymorphic, and interpreting
identified gene variants should be done cautiously. When
possible, parental samples should be used to demonstrate
proper inheritance of biallelic variants. Biochemical
assays may help to complement molecular diagnostics.
We have identified a significant number of patients who
carry only a single novel or rare mutation in CECR1.
These patients should be analyzed for the presence of
structural or non-coding variants in CECR1. Alterna-
tively, we will consider the possibility that single muta-
tions may act as susceptibility alleles for complex forms
of vasculitis. Our study expands on the role of ADA2 in
the pathogenesis of PAN in non-founder populations.
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